World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
68456
World Ranking
17774
National Ranking
592

Overview

Jean-Luc Raoul is affiliated with the Institut de Cancérologie de l'Ouest (ICO) in France. Their research primarily spans the broad field of Medicine, with a focus on Oncology. The scientist has contributed significantly to subfields including Oncology, Surgery, Pulmonary and Respiratory Medicine, Hepatology, and Epidemiology.

Their published work covers a range of topics within cancer research and treatment, notably:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Intraperitoneal and Appendiceal Malignancies
  • Neuroendocrine Tumor Research Advances
  • Gastric Cancer Management and Outcomes
  • COVID-19 and healthcare impacts
  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies

Some of their recent notable publications include:

  • Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, 2022, JAMA Oncology
  • A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers, 2020, European Journal of Cancer
  • Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere, 2020, The Lancet Oncology
  • Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers, 2023, Hepatology
  • Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer, 2021, JAMA Network Open

Jean-Luc Raoul has frequently published in the following venues:

  • Cancers (7 publications)
  • European Journal of Cancer (3 publications)
  • Frontiers in Oncology (2 publications)
  • Case Reports in Oncology (2 publications)
  • European Journal of Surgical Oncology (2 publications)

The scientist frequently collaborates with several coauthors, including:

  • Hélène Senellart
  • Frédéric Dumont
  • Julien Edeline
  • Frédéric Bigot
  • Audrey Blanc-Lapierre

Best Publications

  • Sorafenib in Advanced Hepatocellular Carcinoma

    Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard

  • EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma

    Peter R. Galle;Alejandro Forner;Josep M. Llovet;Vincenzo Mazzaferro

  • FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

    Thierry Conroy;Françoise Desseigne;Marc Ychou;Olivier Bouché

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

    Thierry Conroy;Pascal Hammel;Mohamed Hebbar;Meher Ben Abdelghani

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean

  • Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

    Valérie Vilgrain;Valérie Vilgrain;Helena Pereira;Eric Assenat;Boris Guiu

  • Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

    Jordi Bruix;Jean Luc Raoul;Morris Sherman;Vincenzo Mazzaferro

  • Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon

  • Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.

    Luigi Bolondi;Andrew Burroughs;Jean François Dufour;Peterr R. Galle

  • Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

    Josep M. Llovet;Thomas Decaens;Jean-Luc Raoul;Eveline Boucher

  • Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization

    J.-L. Raoul;B. Sangro;A. Forner;V. Mazzaferro

  • Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

    Sophie Gourgou-Bourgade;Caroline Bascoul-Mollevi;Françoise Desseigne;Marc Ychou

  • Treatment of intermediate-stage hepatocellular carcinoma

    Alejandro Forner;Marine Gilabert;Jordi Bruix;Jean-Luc Raoul

  • Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

    Jean-Luc Raoul;Alejandro Forner;Luigi Bolondi;Tan To Cheung

  • Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

    Erick Gamelin;Remy Delva;Jacques Jacob;Yacine Merrouche

  • Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

    Thierry Conroy;Marie-Pierre Galais;Jean-Luc Raoul;Olivier Bouché

  • Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

    Y Bécouarn;M Ychou;M Ducreux;C Borel

  • Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803

    Olivier Bouché;Jean Luc Raoul;Franck Bonnetain;Marc Giovannini

  • Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

    Julien Edeline;Eveline Boucher;Yan Rolland;Elodie Vauléon

Frequent Co-Authors

Olivier Bouché
Olivier Bouché CHU de Reims
Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Marc Ychou
Marc Ychou University of Montpellier
Josep M. Llovet
Josep M. Llovet University of Barcelona
Eric Raymond
Eric Raymond St. Joseph Hospital
Jordi Bruix
Jordi Bruix University of Barcelona
Juan W. Valle
Juan W. Valle University of Manchester
Michel Ducreux
Michel Ducreux Institut Gustave Roussy
Valérie Boige
Valérie Boige Institut Gustave Roussy
Masatoshi Kudo
Masatoshi Kudo Kindai University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always begin and end with medical school. Today, there are diverse online degree options that open doors to healthcare roles with flexible study options and potentially lower costs. For students mindful of expenses, understanding how much is medical billing and coding school can be a smart first step—these programs are usually shorter and more affordable paths to enter the healthcare field.

Nursing remains a highly sought-after profession, and aspiring nurses are increasingly choosing online programs to balance work and study. Curious about how much is online nursing school? Affordable and accredited programs make it possible to earn your degree without relocating or leaving your job.

Those aiming higher can also consider online nurse practitioner programs, which equip registered nurses with advanced skills and expanded career opportunities. For experienced nurses pursuing leadership, teaching, or research, there are also flexible online phd nursing programs that support continued professional growth.

Best Scientists Citing Jean-Luc Raoul

Trending Scientists

Recently Published Articles